Aspirin and clopidogrel compared with placebo in people with psoriasis
Compares aspirin, clopidogrel and placebo for blood vessel changes in psoriasis.
Plain-language title generated from the registry record
Registry title: A Clinical Trial of Antiplatelets in Psoriasis
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07744191, who can take part
Where in United States
- NYU Langone HealthNew York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NYU Langone Health
- Trial code
- NCT07744191
- Record updated
- 5 August 2026
- Original description
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Crossover Trial of Antiplatelet Therapies in Psoriasis
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.
Inclusion: One of the following:; A history of psoriasis as confirmed by a board-certified dermatologist OR; A history of psoriatic arthritis as confirmed by a board-certified rheumatologist; Age ≥ 18 \& < 90 years; Able and willing to provide written informed consent for the study; English-speaking unless a translated informed consent form is approved; No previous antiplatelet or anticoagulant use for 14 days prior to enrollment.
Exclusion: A prior history of a myocardial infarction, stroke/TIA, or occlusive peripheral arterial disease; Chronic antiplatelet/anticoagulant use that is not able to be stopped at least 14 days prior to study enrollment; Known active cancer receiving treatment; A history of severe bleeding or bleeding disorders; Active gastrointestinal ulcer; Active pathological bleeding; Chronic kidney disease (CrCl < 30ml/min); Congestive heart failure; Known hypersensitivity to or allergy to aspirin, clopidogrel, or any of the components of the study capsules; History of aspirin-exacerbated respiratory disease or asthma induced by salicylates or NSAIDs; Uncontrolled hypertension resting systolic blood pressure > 180 mm Hg or diabetes HbA1c > 10%; Anemia (hemoglobin < 9 mg/dl) or thrombocytopenia (Platelet count <75), or thrombocytosis (Platelet count >600); Pregnancy; Currently breastfeeding; Persons of childbearing potential unwilling to use acceptable contraception during the study.